2006 in cancer

FDA · US: 41 records / 21 drugsHealth Canada · CA: 10 records / 7 drugsEMA · EU: 4 records / 4 drugs

• Oct 6, 2006Vorinostat FDA · US original application approved Primary Cutaneous T-Cell Non-Hodgkin LymphomaZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent…openfda
• Sep 27, 2006Panitumumab FDA · US original application approved Malignant Colorectal NeoplasmVectibix is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of: Adult patients with wild-type RAS (defined as wild-type in…openfda
• Jun 1, 2006Prednisolone FDA · US original application approved Mycosis FungoidesDermatologic Diseases Bullous dermatitis herpetiformis Contact dermatitis Exfoliative erythroderma Mycosis fungoides Pemphigus Severe erythema multiforme…openfda
• Jan 26, 2006Sunitinib FDA · US original application approved Primitive Neuroectodermal Tumortreatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic…openfda
• Jan 26, 2006Sunitinib FDA · US original application approved Renal Cell Carcinomatreatment of adult patients with advanced renal cell carcinoma (RCC).openfda
• Jun 28, 2006Dasatinib FDA · US original application approved cancer not stated in this recordDasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)…openfda
• Jun 1, 2006Prednisolone FDA · US original application approved cancer not stated in this recordAllergic Conditions Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric…openfda
• Apr 11, 2006Mitoxantrone FDA · US original application approved cancer not stated in this recordMitoxantrone injection, USP (concentrate) is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary…openfda
• Jan 26, 2006Sunitinib FDA · US original application approved cancer not stated in this recordtreatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. • adjuvant treatment…openfda
• May 29, 2006Clofarabine EMA · EU centralised approved Acute Lymphoblastic LeukemiaTreatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and…ema
• Dec 15, 2006Celecoxib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-12-15 (see label)openfda
• Dec 8, 2006Bortezomib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-12-08 (see label)openfda
• Dec 4, 2006Fludarabine Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as FLUDARABINE PHOSPHATE FOR INJECTION (DIN 02283859) under ATC L01BB05 FLUDARABINE. Indications are not published in the Drug Product…health-canada-dpd
• Nov 20, 2006Dasatinib EMA · EU centralised approved cancer not stated in this recordSprycel is indicated for the treatment of paediatric patients with: newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic…ema
• Nov 16, 2006Trastuzumab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-11-16 (see label)openfda
• Oct 20, 2006Interferon Beta-1b FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-10-20 (see label)openfda
• Oct 19, 2006Imatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-10-19 (see label)openfda
• Oct 19, 2006Imatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-10-19 (see label)openfda
• Oct 19, 2006Imatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-10-19 (see label)openfda
• Oct 19, 2006Imatinib Mesylate FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-10-19 (see label)openfda
• Oct 19, 2006Imatinib Mesylate FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-10-19 (see label)openfda
• Oct 19, 2006Imatinib Mesylate FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-10-19 (see label)openfda
• Oct 19, 2006Imatinib Mesylate FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-10-19 (see label)openfda
• Oct 19, 2006Imatinib Mesylate FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-10-19 (see label)openfda
• Oct 19, 2006Imatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-10-19 (see label)openfda
• Oct 19, 2006Imatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-10-19 (see label)openfda
• Oct 17, 2006Docetaxel FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-10-17 (see label)openfda
• Oct 11, 2006Bevacizumab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-10-11 (see label)openfda
• Sep 29, 2006Rituximab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-09-29 (see label)openfda
• Sep 29, 2006Rituximab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-09-29 (see label)openfda
• Sep 27, 2006Imatinib Mesylate FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-09-27 (see label)openfda
• Sep 27, 2006Imatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-09-27 (see label)openfda
• Aug 31, 2006Paclitaxel Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as ABRAXANE FOR INJECTABLE SUSPENSION (DIN 02281066) under ATC L01CD01 PACLITAXEL. Indications are not published in the Drug Product…health-canada-dpd
• Jul 31, 2006Sorafenib Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as NEXAVAR (DIN 02284227) under ATC L01EX02 SORAFENIB. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Jul 24, 2006Pegaspargase FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-07-24 (see label)openfda
• Jul 19, 2006Sunitinib EMA · EU centralised approved cancer not stated in this recordGastrointestinal stromal tumour (GIST) Sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST)…ema
• Jul 19, 2006Sorafenib EMA · EU centralised approved cancer not stated in this recordHepatocellular carcinoma Nexavar is indicated for the treatment of hepatocellular carcinoma. Renal cell carcinoma Nexavar is indicated for the treatment of…ema
• Jun 29, 2006Lenalidomide FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-06-29 (see label)openfda
• Jun 22, 2006Sunitinib Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as SUTENT (DIN 02280795) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Jun 22, 2006Sunitinib Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as SUTENT (DIN 02280817) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Jun 22, 2006Sunitinib Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as SUTENT (DIN 02280809) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Jun 20, 2006Bevacizumab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-06-20 (see label)openfda
• Jun 14, 2006Topotecan FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-06-14 (see label)openfda
• Jun 2, 2006Sirolimus FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-06-02 (see label)openfda
• Jun 2, 2006Sirolimus FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-06-02 (see label)openfda
• Mar 22, 2006Docetaxel FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-03-22 (see label)openfda
• Mar 1, 2006Cetuximab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-03-01 (see label)openfda
• Mar 1, 2006Cetuximab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-03-01 (see label)openfda
• Feb 28, 2006Rituximab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-02-28 (see label)openfda
• Feb 10, 2006Bicalutamide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as TEVA-BICALUTAMIDE (DIN 02270226) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the…health-canada-dpd
• Feb 10, 2006Rituximab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-02-10 (see label)openfda
• Feb 8, 2006Bicalutamide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as PMS-BICALUTAMIDE (DIN 02275589) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the…health-canada-dpd
• Feb 1, 2006Irinotecan Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION USP (DIN 02258218) under ATC L01CE02 IRINOTECAN. Indications are not published in the Drug Product…health-canada-dpd
• Jan 24, 2006Thyrotropin Alfa FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2006-01-24 (see label)openfda
• Jan 6, 2006Anagrelide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as PMS-ANAGRELIDE (DIN 02274949) under ATC L01XX35 ANAGRELIDE. Indications are not published in the Drug Product Database — see the Health…health-canada-dpd

RegulatoryAll 2006 records with filters →

Studies

2,750

Interventional

2,429

Phase III

458

Industry-led

777

With posted results

834

Countries with sites

87

Published source: clinicaltrials · first_posted_date as posted